Leading expert Mia Kontio from THL says that it is starting to look more and more strong that the entire Finnish adult population has been vaccinated at least once by the end of June.
It starts to show it is even more likely that 5.8–7.6 million doses of coronary vaccine will arrive in Finland by the end of June. This means that every adult who wants an adult coronary vaccine will also receive the vaccine by the end of June.
Read more: Light at the end of the tunnel! According to the THL, the entire adult population may have been vaccinated by the end of June
Even if a second dose of about one million is taken out of the amount, the amount is well enough to vaccinate every adult once.
This is the assessment of THL’s leading expert on vaccine logistics Mia Kontio To Ilta-Sanomat.
– We are moving forward at a really good pace. Summer now looks much better! Yes, it must affect the restrictions that a large part of the population has been vaccinated, because vaccinations seek exactly that freedom from restrictions, Kontio said with pleasure.
Read more: THL: More than 636,300 people in Finland have received a coronary vaccine
More good news came on Tuesday when pharmaceutical company Pfizer announced it would be able to deliver 10 million more doses than planned to the EU by the end of June.
European President of the Commission Ursula von der Leyen said the news agency To Reutersthat the EU will receive up to more than 200 million doses from Pfizer between the beginning of April and the end of June.
Finland’s share of this is 2.46 million doses, which is extra compared to the previous estimate of about 400,000 doses.
According to Kontio, Pfizer announced that it would be able to deliver more than 50,000 more doses than planned in weeks 12-13.
– That was really positive news! Our estimate is that in Finland, all people over the age of 70 have received the first dose by mid-April. It won’t be many weeks. We get there by leveling the gap between hospital districts and municipalities.
– It is a big deal when the most vulnerable group is definitely protected. It reduces the number of deaths and serious illnesses, Kontio emphasizes.
Vaccine supplies the large increase is mainly due to a significant increase in Pfizer-Biontech vaccine production. A second production line has been built at Pfizer’s Puursin plant in Belgium, and Biontech’s plant in Marburg, Germany, will begin feeding large quantities of the vaccine by April.
In addition, there will be Moderna, whose deliveries to Europe will gradually increase as it gets a big production contract with the US fulfilled. The new one will be Johnson & Johnson, which provides final protection for a single dose and was granted a marketing authorization in the EU last week.
The biggest source of uncertainty for the final vaccine volume has been AstraZeneca in the midst of the uproar over the past few days due to suspected blood clots.
– AstraZeneca is a variable in the equation. Its deliveries have the greatest uncertainties of all, Kontio said.
The production uncertainty of AstraZeneca, one of the adenovirus vaccines, is due to the fact that live virus is needed to make the vaccine. Virus cultures are more sensitive to production disturbances and quality variation.
Instead, mRNA vaccines (e.g., Pfizer and Moderna) are prepared completely synthetically. The method is not as susceptible to production disorders as an adenovirus vaccine cultured from a live virus. If only the raw material is enough, an agreed amount of homogeneous vaccine will be produced at the Pfizer-Biontech and Moderna plants.
According to Kontion it is already clear that AstraZeneca will lose its status as a “folk vaccine”. According to the original plan, most Finns would have been vaccinated with AstraZeneca.
– Pfizer-Biontech is now taking its place. Absolutely most Finns are vaccinated with this vaccine, Kontio says.
Next on the EU approval list is probably the German CureVac. According to Kontio, however, there has been a bit of a backlash in its development. Kontio estimates that CureVac may not be granted a marketing authorization until June, which means that it will not have time to take part in the vaccination efforts in the first half of the year.
However, the message of the Department of Health and Welfare’s THL is now clear: when the recommendations and restrictions can be followed for a while, practically everyone who has been vaccinated will have been vaccinated in just three months. At the latest, the return to normal should begin.
– It is still really difficult to assess at what stage any restrictions can be relaxed. Britain and Israel are far ahead in vaccinations, so we will get information about those countries. It is still unclear how much a vaccinated person can re-infect. Even if our own protection is good, the exact infectivity is not yet known, Kontio says.
Vaccine Research Center manager Mika Rämet trusts that once the adult population has been vaccinated, society will slowly begin to open up.
– Let’s go to movies, theaters, restaurants and maybe even terraces again. Infection and death rates in Britain, for example, give great confidence that infections that require hospitalization can be reduced and at the same time the burden of disease can be reduced here, Rämet says.
– The essential thing is that the first dose is given to as many people as possible. Even then, protection is remarkably good and restrictive measures can be gradually lifted. However, it is not a bad practice at all for hand-held bottles to remain prominent in stores, Rämet continues.
However, Rämet points out that it is not possible to get rid of the corona completely quickly.
– People under the age of 16 are not vaccinated yet, and it will take time before people under the age of 12 can be vaccinated, Rämet says.
Source site www.is.fi